CMN Weekly (20 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 20, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
CorriXR Therapeutics
Company Type: Therapeutics
Main focus: Highly selective CRISPR-Cas therapies for cancer
Company stage: Pre-clinical
Diseases: Solid tumours
Genome-editing tool: CRISPR-Cas
Funding stage: Seed Funding
Location: Newark, Delaware, USA
Website: https://www.corrixr.com/
Pipeline:
Partners:
CorriXR Therapeutics is a pre-clinical-stage therapeutics company that leverages CRISPR-Cas to specifically hit cancer cells - sparing healthy cells - by targeting cancer-specific mutations in a selected target. CorriXR's current lead target is the NRF2 gene.
